IFNA1 and hemophagocytic syndrome: Therefore, pretransplant use of ruxolitinib to suppress hyperactive IFN responses may allow better immune reconstitution by controlling the hyperinflammatory process and reducing the posttransplant complications as shown for patients with hemophagocytic lymphohistiocytosis (HLH) [71].